文献速递疼痛医学

线粒体靶向抗氧化剂MitoVitE减轻紫杉醇诱导的氧化应激、线粒体损伤及大鼠机械超敏

MitoVitE, a mitochondria-targeted antioxidant, limits paclitaxel-induced oxidative stress and mitochondrial damage in vitro, and paclitaxel-induced mechanical hypersensitivity in a rat pain model.
PubMed 文献 · Br J Anaesth · 2016-01-01

该研究在体外观察MitoVitE与Trolox对紫杉醇所致大鼠背根神经节细胞线粒体损伤的保护作用,并在大鼠疼痛模型中比较MitoVitE与度洛西汀对紫杉醇诱导机械超敏的影响。结果显示MitoVitE可减轻线粒体损伤且不影响癌细胞毒性,在大鼠中效果与度洛西汀相似。

要点

  • MitoVitE减轻紫杉醇所致DRG细胞线粒体膜电位丢失和代谢活动下降。
  • MitoVitE不降低紫杉醇对卵巢癌细胞的毒性。
  • 大鼠中MitoVitE缓解紫杉醇诱导机械超敏,程度与度洛西汀相似。

核心结论

  • 紫杉醇影响DRG细胞线粒体功能和谷胱甘肽,MitoVitE可改善而Trolox不能,且不降低癌细胞毒性。
  • 在大鼠中MitoVitE缓解紫杉醇诱导的机械超敏,程度与度洛西汀相似。
  • 线粒体是紫杉醇所致损伤的机制靶点,线粒体靶向抗氧化剂可能成为未来治疗策略。

研究设计与样本

  • 体外研究:大鼠DRG细胞暴露于紫杉醇,加或不加MitoVitE或Trolox,测线粒体功能。
  • 体外研究:癌细胞系暴露于紫杉醇与MitoVitE或Trolox,测细胞杀伤。
  • 大鼠在体研究:紫杉醇累积剂量8 mg kg-1,每日加MitoVitE 2 mg-1 kg day-1、度洛西汀10 mg kg-1 day-1或溶媒对照,每两天测机械缩足阈值。

主要发现

  • 紫杉醇导致DRG细胞膜电位丢失,100 µM时中位[范围]变化为61[44-78]%,P < 0.0001。
  • MitoVitE改善膜电位变化至86[62-104]%,Trolox为46[46-57]%。
  • 紫杉醇所致代谢活动和谷胱甘肽下降(均P < 0.0001)被MitoVitE减轻而Trolox不能。
  • 卵巢癌细胞中MitoVitE或Trolox不影响紫杉醇毒性;乳腺癌细胞中Trolox略降低毒性。
  • 大鼠注射后6小时缩足阈值曲线下面积均值(SD):对照110(5),MitoVitE 145(10),度洛西汀156(13),P < 0.0001。

临床怎么用

  • 线粒体靶向抗氧化剂可能作为紫杉醇所致神经病理性疼痛的潜在治疗策略。
  • MitoVitE在动物模型中缓解机械超敏效果与度洛西汀相似,但尚未进入临床。

局限性

  • 研究为体外细胞实验和大鼠模型,结果不能直接外推至临床患者。
  • 样本量、盲法及随机化等设计细节原文摘要未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neuropathic pain is a common side-effect of chemotherapy. Although precise mechanisms are unclear, oxidative stress and mitochondrial damage are involved. We investigated whether the mitochondria targeted antioxidant, MitoVitE, provided better protection against paclitaxel-induced mitochondrial damage in rat dorsal root ganglion (DRG) cells, than a non-targeted form of vitamin E, Trolox. We also determined whether MitoVitE, compared with duloxetine, could limit paclitaxel-induced mechanical hypersensitivity in rats. METHODS: Mitochondrial function was measured in DRG cells exposed to paclitaxel with and without MitoVitE or Trolox. The effect of MitoVitE or Trolox on paclitaxel-induced cell killing in cancer cell lines was also determined. Rats received a cumulative dose of 8 mg kg-1 paclitaxel plus either MitoVitE (2 mg-1 kg day-1), duloxetine (10 mg kg-1 day-1) or vehicle control daily. Mechanical hind paw withdrawal thresholds were measured every two days. RESULTS: Paclitaxel caused loss of membrane potential in DRG cells. At 100 µM paclitaxel median [range] change was 61[44-78]%, P < 0.0001, which was ameliorated by MitoVitE (86[62-104]%) but not Trolox (46[46-57]%). Similarly, loss of metabolic activity and glutathione induced by paclitaxel (both P < 0.0001) were reduced by MitoVitE but not Trolox. Cytotoxicity of paclitaxel was not affected by co-exposure of ovarian cancer cells to either MitoVitE or Trolox, but was slightly reduced against breast cancer cells, in the presence of Trolox. Mean (SD) areas under the curve of withdrawal thresholds at 6 h after injection in rats given paclitaxel + control, or + MitoVitE (P < 0.0001) or + duloxetine (P < 0.0001) were 110 (5), 145 (10) and 156 (13) respectively. CONCLUSIONS: Paclitaxel affected mitochondrial function and glutathione in DRG cells, which was abrogated by MitoVitE but not Trolox, without decreasing cancer cell cytotoxicity. In rats, paclitaxel-induced mechanical hypersensitivity was ameliorated by MitoVitE treatment to an extent similar to duloxetine. These data confirm mitochondria as a mechanistic target for paclitaxel-induced damage and suggest mitochondria targeted antioxidants as future therapeutic strategies.

来源:Br J Anaesth,查看原文。版权归原作者所有。

引用

  1. McCormick B, Lowes DA, Colvin L, et al. MitoVitE, a mitochondria-targeted antioxidant, limits paclitaxel-induced oxidative stress and mitochondrial damage in vitro, and paclitaxel-induced mechanical hypersensitivity in a rat pain model. Br J Anaesth. 2016. PMID: 27799181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。